Katie Lee

Katie Lee

Auto-generated profile, based on publicly available information

Katie Lee

Department of Dermatology and

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cell Reports
Verified
Journal Article
Open access
XGXia Gao
Xia Gao
KLKatie Lee
Katie Lee
MRMichael A. Reid
Michael A. Reid
SSSydney M. Sanderson
Sydney M. Sanderson
CQChuping Qiu
Chuping Qiu
JLJason W. Locasale
Jason W. Locasale
Cell proliferation can be dependent on the non-essential amino acid serine, and dietary restriction of serine inhibits tumor growth, but the underlying mechanisms remain incompletely understood. Using a metabolomics approach, we found that serine deprivation most predominantly impacts cellular acylcarnitine levels, a signature of altered mitochondrial function. Fuel utilization from fatty acid, glucose, and glutamine is affected by serine deprivation, as are mitochondrial morphological dynamics leading to increased fragmentation. Interestingly, these changes can occur independently of nucleotide and redox metabolism, two known major functions of serine. A lipidomics analysis revealed an overall decrease in ceramide levels. Importantly, supplementation of the lipid component of bovine serum or C16:0-ceramide could partially restore defects in cell proliferation and mitochondrial fragmentation induced by serine deprivation. Together, these data define a role for serine in supporting mitochondrial function and cell proliferation through ceramide metabolism.

7 October 2021 in Blood
Verified
Journal Article
Open access
PDF file
JPJoonhee Park
Joonhee Park
JDJay Daniels
Jay Daniels
TWTim Wartewig
Tim Wartewig
KRKimberly G. Ringbloom
Kimberly G. Ringbloom
MMMaria Estela Martinez-Escala
Maria Estela Martinez-Escala
JCJaehyuk Choi
Jaehyuk Choi
Cutaneous T-cell lymphomas (CTCLs) are a clinically heterogeneous collection of lymphomas of the skin-homing T cell. To identify molecular drivers of disease phenotypes, we assembled representative samples of CTCLs from patients with diverse disease subtypes and stages. Via DNA/RNA-sequencing, immunophenotyping, and ex vivo functional assays, we identified the landscape of putative driver genes, elucidated genetic relationships between CTCLs across disease stages, and inferred molecular subtypes in patients with stage-matched leukemic disease. Collectively, our analysis identified 86 putative driver genes, including 19 genes not previously implicated in this disease. Two mutations have never been described in any cancer. Functionally, multiple mutations augment T-cell receptor–dependent proliferation, highlighting the importance of this pathway in lymphomagenesis. To identify putative genetic causes of disease heterogeneity, we examined the distribution of driver genes across clinical cohorts. There are broad similarities across disease stages. Many driver genes are shared by mycosis fungoides (MF) and Sezary syndrome (SS). However, there are significantly more structural variants in leukemic disease, leading to highly recurrent deletions of putative tumor suppressors that are uncommon in early-stage skin-centered MF. For example, TP53 is deleted in 7% and 87% of MF and SS, respectively. In both human and mouse samples, PD1 mutations drive aggressive behavior. PD1 wild-type lymphomas show features of T-cell exhaustion. PD1 deletions are sufficient to reverse the exhaustion phenotype, promote a FOXM1-driven transcriptional signature, and predict significantly worse survival. Collectively, our findings clarify CTCL genetics and provide novel insights into pathways that drive diverse disease phenotypes.

9 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
KLKatie Lee
Katie Lee
MEMark G. Evans
Mark G. Evans
LYLei Yang
Lei Yang
SNSpencer Ng
Spencer Ng
CSCaroline Snowden
Caroline Snowden
JCJaehyuk Choi
Jaehyuk Choi
Primary cytotoxic T cell lymphomas (CTCLs) are a rare subset of aggressive, poor-prognosis T-cell lymphomas targeting the skin; they include primary cutaneous γδT-cell lymphoma, primary cutaneous VD8+ aggressive epidermotropic T cell lymphoma (PCAETCL), and cytotoxic CTCL not otherwise specified. Lee et al report that all 3 subsets have JAK-STAT activation, but PCAETCL uniquely carries JAK2 gene fusions that may render them especially susceptible to JAK inhibitors.

1 November 2021 in Veterinary Clinics of North America: Food Animal Practice
Verified
Journal Article
Closed access
BKBritteny Kyle
Britteny Kyle
KLKatie Lee
Katie Lee
SPStephen Pernal
Stephen Pernal